Prostate cancer chemoprophylaxis: a review of clinical and preclinical data

Review of clinical and experimental data on medications, nutritional and non nutritional substances, that able to slow down cancerogenesis in prostate. Review and classification of medications and substances inhibiting prostate cancerogenesis in clinical and preclinical trials with perspective of further investigation and practical application as a prostate cancer chemoprophylaxis option. Wide application of chemoprophylaxis in addition to screening methods among male population must have a good efficacy in prostate cancer propylaxis. In the range of chemopropylaxis medications nowadays we have only inhibitors 5-a reductase. Finasteride in clinical trials of the highest levels prevented prostate cancer. However finasteride has serious side effects which makes possibility of using it as a primary prophylaxis method in healthy males doubtful. Thereby search of new and safe chemoprophylactic medicines is actual problem of oncourology. Now we can count a perspective agents less toxic nutritional substances, that proved their efficacy in epidemiological, clinical and preclinical trials their capability to inhibit cancerogenesis. We can number llycopene, soy isoflavones, tea catechins. For definitive proof of efficacy of these substances further long-term interventional clinical trials are required. However, taking into account safety and positive features of llycopene, soy isoflavones, tea catechins we can recommend this substances as a nutritional factor for prostate cancer prevention.